Skip to main content
. Author manuscript; available in PMC: 2010 Feb 27.
Published in final edited form as: Invest New Drugs. 2008 Jul 11;27(1):53–62. doi: 10.1007/s10637-008-9154-z

Table 2.

Patient demographics and characteristics

Characteristic n (%)
Number of patients 24
Total number of courses 64
Number courses delivered per patient
 Median 2
 Range 1–6
Patients receiving more than or equal to three cycles of therapy 9
Sex
 Male 13 (54)
 Female 11 (46)
Age
 Median (in years) 54
 Range (in years) 20–75
ECOG performance statusa
 0 5
 1 17
 2 2
Previous treatment
 Patients with prior chemotherapy treatments 21 (88)
 Median (range) of chemotherapy treatments 2 (0–4)
 No prior therapy (including targeted therapy, chemotherapy and radiotherapy) 2
 Prior radiotherapy 15 (63)
Tumor type
 Melanoma 4
 Upper GI tractb 3
 Sarcomac 3
 Colon 2
 Head and neck 2
 Pancreatic cancer 2
 Otherd 7
a

ECOG Eastern Cooperative Oncology Group

b

Includes one each esophageal, gastroesophageal and gastric carcinomas

c

Includes one each of angiosarcoma, Ewing's sarcoma and leiomyosarcoma

d

Other tumor types include one each of: adenocarcinoma of the breast, astrocytoma, germinoma, endometrial, ovarian, non-small cell lung, and renal cell carcinoma